Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Jennifer Lauren Kamens
- Target Recruit Count
- 34
- Registration Number
- NCT05101551
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 456
- Registration Number
- NCT05092360
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 24
- Registration Number
- NCT05083000
- Locations
- 🇮🇳
Christian Medical College, Vellore, Tamil Nadu, India
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT04994977
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
A Study of N9 Chemotherapy in Children With Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT04947501
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT04943627
- Locations
- 🇦🇲
Hematology Center after prof. R. Yeolyan, Yerevan, Armenia
🇦🇲National Center of Oncology named after V.A. Fanarjian, Yerevan, Armenia
🇺🇸Optimum Research (Southwest Women's Oncology Center), Albuquerque, New Mexico, United States
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 421
- Registration Number
- NCT04908787
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Topotecan and Melphalan for Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT04799002
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2023-08-15
- Target Recruit Count
- 76
- Registration Number
- NCT04768296
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States
🇺🇸Summa Health, Akron, Ohio, United States
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT04697628
- Locations
- 🇺🇸
Willis-Knighton Physician Network/Gynecologic Oncology Associates, Shreveport, Louisiana, United States
🇺🇸Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇮🇹Fondazione Policlinico Universitario Agostino, Roma, Other, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.